BioCentury
ARTICLE | Clinical News

Latanoprost punctal plug delivery system: Phase II data

December 3, 2012 8:00 AM UTC

Data from all patients with open-angle glaucoma or ocular hypertension regardless of plug loss (n=57) in the open-label, U.S. Phase II PPL GLAU 12 trial showed that 141 µg latanoprost delivered via punctal plugs in the upper and lower puncta (95/46 µg) reduced mean IOP from baseline to week 4, the primary endpoint, by 5.7 mmHg. The 190 µg latanoprost dose (95/95 µg) reduced mean IOP by 5.5 mmHg at week 4. On secondary endpoints, 141 µg latanoprost reduced mean IOP by 4.3 mmHg at week 8 and 3.9 mmHg at week 12. The 190 µg dose reduced mean IOP by 4.3 mmHg at week 8 and 4.2 mmHg at week 12. ...